The Reciprocal Relations Between Psychosocial Characteristics and the Progression of Vestibulodynia

April 6, 2022 updated by: Ahinoam Lev-Sagie, Meir Medical Center

The Reciprocal Relations Between Psychosocial Characteristics and the Progression of Vestibulodynia, and the Mental Health of the Patient

The proposed study will evaluate how personality characteristics, cognitive factors and the emotional and behavioral responses of patients with provoked vestibulodynia (localized provoked vulvodynia) influence the natural history of the syndrome, patients' adherence to therapeutic interventions, provoked pain levels, pelvic floor rehabilitation, emotional health and sexual functioning.

Study Overview

Detailed Description

Provoked vestibulodynia (PVD) is the term describing a syndrome of provoked, localized allodynia of the vestibule of the vulva, not explained by another condition, and lasting more than 3 months. PVD is not a defined disease but rather a symptom. It is thought that PVD represent a group of distinct disorders that have been classified together because they produce pain in the same anatomic location.

Studies found that different factors such as genetic, inflammation, recurrent vaginitis, allergy, trauma, emotional and neural may be involved in the development of PVD.

Treatment of PVD is generally predicated on a trial and error basis, because the pathogenesis is not defined. The result is that many forms of therapeutic interventions have been used, yet the evidence remains largely inconclusive, the response rates varies considerably, and many women do not respond to any of the treatments. It is therefore important to recognize which factors mediate the syndrome's severity, and influence the effectiveness of treatments.

The proposed study will evaluate how different patients' characteristics (personality, cognitive) and responses (emotional and behavioral) influence the natural history of the syndrome and the response to treatment. The study is based on the bio-psycho-social model and the adult attachment theory, which integrates psychosocial factors to define susceptibility to acquire pain disorders and predict response to therapy. According to this model, choosing effective coping strategy during a crisis and receiving support from a spouse are vital for recovery.

The study aim to:

  1. Characterize interactions between attachment patterns, personality types, cognitive factors (catastrophization, coherence, and partner's support), emotional factors (coping strategies, emotional stress and satisfaction from intimate relationship) to pain levels, pelvic floor hypertonicity, sexual function and patient's emotional health.
  2. Examine whether treatments' results are influenced by personality, relationship, cognitive, emotional and behavioral characteristics of the patient.
  3. Recognize factors that influence the extent of adherence to treatment.
  4. Characterize patients' profile in regard to successful outcome.

Methods Patients will be recruited from the clinic for vulvovaginal disorders in Clalit Healthcare services in Jerusalem. The diagnostic procedures, patients' sub-classification and the proposed treatments in the current protocol are identical to those currently used in the clinic. Each patient will undergo a standard evaluation which includes: detailed history intake, vulvar and vaginal examination, evaluation of vestibular tenderness (Q tip test), pelvic floor musculature tenderness examination, vaginal pH measurement, saline and 10% potassium hydroxide microscopy, yeast and bacterial cultures and STD screening.

Patients who fulfill diagnostic criteria of PVD and who will be willing to participate in the study will be asked to sign an informed consent and complete the following self-administered intake questionnaires:

  • Socio-demographic questionnaire (age, marital status, religios, PVD onset, health status, education etc.)
  • Close Relations Experiences questionnaire
  • Five Factor Inventory -NEO-FFI
  • Pain catastrophizing questionnaire
  • Sense of Coherence Scale
  • Ways of giving support questionnaire
  • COPE -Multidimensional Coping Inventory
  • Semantic Differential Measure of Marital Satisfaction
  • PSS-10 - Perceived Stress Scale
  • FSFI-Female Sexual Function Index

Instructions for treatment will be given in regards to the diagnosis. Patients will be instructed to schedule follow-up appointments at 3,6,9, and 12 months. During follow-up appointments they will be assessed in regard to vestibular tenderness (using various parameters), as well as by the same questionnaires. Additional treatment will be recommended according to medical status, in an identical way to this routinely used in the clinic.

Study Type

Observational

Enrollment (Actual)

113

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Jerusalem, Israel
        • Merkaz Briot Haisha, Ramat Eshkol

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Patients will be recruited from the clinic for vulvovaginal disorders in Clalit Healthcare services in Jerusalem.

Description

Inclusion Criteria:

  1. A history of 3 months or more of vulvar pain suggestive of PVD, i.e. symptoms of pain on vaginal penetration (insertional dyspareunia and/or pain with tampon insertion).
  2. On exam, tenderness localized within the vestibule when being touched with a cotton-tip applicator.
  3. No identifiable cause for the pain, such as vulvovaginal candidiasis, vaginal atrophy, desquamative inflammatory vaginitis (DIV), herpes, dermatitis or vulvar dystrophy.

Exclusion Criteria:

  1. other causes for vulvar pain
  2. pregnancy or a planned pregnancy in the upcoming year
  3. diagnosis of chronic disease that may affect central nervous system or general function.
  4. usage of psychiatric medications or those affecting pain modulation.
  5. unprovoked or mixed vulvodynia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Hypertonic pelvic muscle dysfunction
In this subgroup, pelvic floor (PF) muscles become tight and tender. Typically, the pain is much worse at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule.
Hormonally mediated PVD
The pain began while taking hormonal contraceptive or other medications that affect hormones, after removal of ovaries, breastfeeding or menopause. The entire vestibule is tender and vestibular mucosa is often dry and thin.
Neuroproliferative PVD
In this condition, we speculate that women have an increased number of nociceptors in the vestibular mucosa. Pain is primary and there is tenderness of the entire vestibule.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of measure of Q tip test assessing pain intensity
Time Frame: Change in measure between recruitment to 3 months, 6 months , 9 months and 12 months
The exam is performed by touching the vestibule with a cotton-tip applicator in 6 defined points (2,5,6,7, 10 and 12),while the patient is being asked to rate the intensity of pain verbally from 0 to 10 at each point.
Change in measure between recruitment to 3 months, 6 months , 9 months and 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measurement of vestibular tenderness using a vulvar algesiometer
Time Frame: Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.
Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.
Change of pain using Visual analog scale
Time Frame: Change in VAS between recruitment to 3 months, 6 months , 9 months and 12 months
Change in VAS between recruitment to 3 months, 6 months , 9 months and 12 months
Adherence to therapy
Time Frame: Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.
Adherence to therapy will be assessed by calculating attendance to planed appointments (physical therapy, medical appointments and LLL treatments)
Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.
Female sexual function index questionnaire
Time Frame: Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.
Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.
Pelvic floor hypertonicity measurements
Time Frame: Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.
Pelvic floor muscle tonicity will be evaluated using manual palpation of the muscles by the physician.
Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.
Brief Symptom Inventory-18 questionnaire (evaluating emotional symptoms)
Time Frame: Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.
Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 30, 2016

Primary Completion (Actual)

December 1, 2020

Study Completion (Actual)

December 1, 2021

Study Registration Dates

First Submitted

September 2, 2016

First Submitted That Met QC Criteria

September 2, 2016

First Posted (Estimate)

September 8, 2016

Study Record Updates

Last Update Posted (Actual)

April 8, 2022

Last Update Submitted That Met QC Criteria

April 6, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0089-16-COM1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Localized Provoked Vulvodynia

Clinical Trials on Pelvic floor physical therapy

3
Subscribe